Stockreport

Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular ...

Genmab A/S - American Depositary Shares  (GMAB) 
PDF epcoritamab in combination with rituximab-lenalidomide (R ) experienced a 95% overall response rate (ORR) Results from the optimization cohort of the EPCORE™ NHL- 1 st [Read more]